---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-049406"
form_type: "8-K"
ticker: "BNBX"
cik: "0000744452"
company_name: "BNB PLUS CORP."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T06:34:47.240397+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Applied DNA Q2 fiscal 2025 revenue up 6% to $983k; net loss narrows to $3.3M

## Summary
- Total revenues $983k (+6% YoY); LineaRx up 44% while MDx testing fell 33%.
- Net loss $3.3M vs $4.5M prior year; operating loss $3.5M; adjusted EBITDA -$3.3M.
- Cash $6.8M at quarter end; expects quarterly cash burn to decline starting June 30, 2025.
- GMP Site 1 validated; annual revenue capacity $10M-$30M; new customer orders for LineaDNA.
- Submitted H5N1 diagnostic validation to NYSDOH; investor call on June 3, 2025.

## SEC filing metadata
- accession: 0001104659-25-049406
- form_type: 8-K
- ticker: BNBX
- cik: 0000744452
- company_name: BNB PLUS CORP.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744452/000110465925049406/0001104659-25-049406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744452/000110465925049406/tm2515261d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-049406
- JSON: https://secwatch.observer/filing/0001104659-25-049406.json
- Plain text: https://secwatch.observer/filing/0001104659-25-049406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.